Direct acting oral anticoagulants (DOACs) should not be used in patients with antiphospholipid syndrome (APS) due to a high risk of thrombotic events, the Therapeutic Goods Administration (TGA) has advised. In a new safety advisory statement the regulator says apixaban (Eliquis), dabigatran etexilate (Pradaxa) and rivaroxaban (Xarelto) are not recommended in patients with APS, particularly ...
Don’t use DOACs in patients with APS, regulator advises
By Michael Woodhead
27 Aug 2019